BIOTECH LEADERS AGENDA

Choose your topic ...            Biotech            Healthtech           Medtech

*** 17:30 - 20:00 Tuesday 10th October - Stay with us for the networking reception ***

Biotech_Leaders_horizontal

Day 1 – Tuesday 10th October

08:50 Welcome Address

Josh Dance, SVP, LSX


09:00 Live Opening Of The Nasdaq Nordic Markets & Nasdaq Welcome 

Carsten Borring, Head of Listing & Capital Markets, NASDAQ Copenhagen 
Carsten Borring, Head of Listings & Capital Markets, Nasdaq Copenhagen


09:10 Back Bay Welcome Address

Jonathan Gertler, CEO, BackBay Life Science Advisors 

Jonathan Gertler, Managing Partner & CEO, Back Bay Life Science Advisors 300x


09:20 Unleashing The Global Potential Of The Nordic Life Science Markets Through Strategic Internationalization 

The Nordic region has long been recognized as a global leader in innovation, sustainability, and quality of life, and has also emerged as a hotbed for life science innovation and entrepreneurship with an increasing number of startups. The Nordic region shares a highly interconnected business environment that facilitates cross-border collaboration and knowledge exchange, creating a unique ecosystem that fosters innovation and entrepreneurship, attracting investors and partners from around the world. Despite these advantages, however, the Nordic life science markets face a number of challenges in their efforts to grow and internationalize. This keynote discussion will explore the current state of the Nordic life science markets, including their strengths and weaknesses, and discuss strategies for growing and globalizing the industry in the years ahead.
  • What are the current challenges facing the Nordic life science markets, and how can we address them?
  • What are the unique strengths of the Nordic life science industry that can be leveraged for international expansion?
  • What strategies can Nordic life science companies adopt to successfully enter and compete in international markets?
  • How can Nordic countries collaborate to build a stronger and more competitive life science ecosystem?
  • What role can government policies and initiatives play in supporting the growth and internationalisation of the Nordic life science markets?
Keld Flintholm Jorgensen, EVP & CBO, Lundbeck 
Carsten Borring, Head of Listings & Capital Markets, NASDAQ Copenhagen 
Henrijette Richter
, Managing Partner, Sofinnova Partners 
Nanna Lüneborg
, General Partner, Forbion 
Jonathan Gertler
, CEO, BackBay Life Science Advisors
Keld Flintholm Jørgensen, EVP & CBO, LundbeckCarsten Borring, Head of Listings & Capital Markets, Nasdaq CopenhagenHenrijette-Richter--Managing-Partner--Sofinnova-ConvertImageNanna Lüneborg, General Partner, ForbionJonathan Gertler, Managing Partner & CEO, Back Bay Life Science Advisors 300x


10:10 How Can Nordic Life Sciences Continue To Be A Global Leader? 

AstraZeneca has a bold aspiration to launch 15 new medicines over the coming years and become carbon-neutral. As a Swedish-British company with more than 84.000 employees globally, the company plays a leading role in the Nordics as well as global life sciences. With increased globalization and competition, what is needed if the Nordics should continue to be a leader within life sciences?

Christof Bischoff, Country Director, Denmark, AstraZeneca  

Christof Bischof


10:30 Morning Break


11:00 The Fundraising Ecosystem For Nordic Life Sciences And Raising Capital During Turbulent Times  

The Nordic region continues to be a beacon of innovation with private stage biotechs and startups continually raising capital, but in 2023 how are some of Europe’s leading investors viewing the field? This panel will discuss how investors are allocating their capital, hot trends to look out for, and how best private stage biotechs can utilise their capital efficiently as we head into 2024 and beyond. 
  • How are investors viewing the field of the Nordic life sciences as an attractive region to invest in?
  • What has got some of the leading investors in the space excited this year, and what are they going to be on the lookout in 2024?
  • What have we learned in terms of navigating the private markets in 2023 and how can biotechs be best prepared for the future?
Moderator: Bill Hicks, Co-chair Securities and Capital Markets Practice Group, Mintz
Camilla Petrycer Hansen, Principal Seed Investments, Novo Holdings 
Charles Conn
, Partner, Monograph Capital
Ingrid Teigland Akay
, Managing Partner, Hadean Ventures 
Claudio Costa
, Operating Partner, Jeito Capital 
Christina Takke
, Managing Partner, V-Bio Ventures 
Bill Hicks, Co-Chair Securities and Capital Markets Practice Group, MintzCamilla Petrycer Hansen, Principal Seed Investments, Novo Holdings Charles Conn, Co-founder and Partner, Monograph CapitalIngrid Teigland Akay, Managing Partner, Hadean VenturesClaudio Costa, Operational Investor, Jeito CapitalChristina Takke, Managing Partner, V-Bio Ventures


11:50 Thinking Outside The Box: How Best To Prepare For Partnering And Investment   

Founders in the biotech industry are no strangers to challenges. Success is impossible to come by without substantial investment, time and technical expertise. Although life science startups managed to come out relatively unscathed last year, the enduring economic climate is turning fundraising and partnering into a never-ending marathon. Panellists discuss how best biotechs can continue to position themselves for both partnering and investment, innovating for the future, and ultimately coming out on top.
  • How to reduce commercial risk while running your business  
  • What are the expectations of pharma BD and investors on the commercial maturity/understanding at different development stages?  
  • How to effectively build relationships with BD and investors 
Moderator: Stephanie Mattsson, Director, MSC Nordics 
Rasmus Just, Global Head BD&L, ALK 
Sebastian Brunemeier, General Partner, Healthspan Capital
Jacob Michlewicz, CFO, Anocca
Magnus Persson, Founding Partner, Eir Ventures  
Stephanie Mattsson, Director, MSC Nordics Rasmus Just, Global Head BD&L, ALK  Sebastian Brunemeier, General Partner, Healthspan CapitalJacob Michlewicz, CFO, Anocca Magnus Persson, Founding Partner, Eir Ventures


12:40 Lunch Break


13:45 The Business Of Biotech: A Day In The Life Of A Public Biotech CEO. Advice And Lessons Learned 
  • What's one leadership lesson you've learned in your career?
  • As a leader, what has been the most significant barrier in your career
  • How do you think about company growth?
  • How are you currently navigating fundraising?
  • What advice would you give to the next generation of leaders?
Moderator: Deborah Sterling, Director, Sterne Kessler 
Renée Aguiar-Lucander
, CEO, Calliditas Therapeutics 
Johan Wäborg
, CEO, Iconovo 
Søren Tulstrup
, CEO, Hansa Biopharma 
Hans Schambye
, CEO, Galecto 
Deborah Sterling, Director, Sterne Kessler Renee Aguiar-Lucander, CEO, Calliditas TherapeuticsJohan Wäborg, CEO, Iconovo Søren Tulstrup, CEO, Hansa Biopharma  Hans Schambye, President & CEO, Galecto

14:40 Beyond The Double Helix: Boldly Advancing The Future Of Cell And Gene Therapies

Successful clinical trials have shown industry stakeholders the value cell and gene therapy offers patients now and as the path of future medicine. Despite the clinical benefits, CGT has not yet achieved significant market penetration. In addition to struggling with production roadblocks, companies also face pricing issues and a global healthcare system unprepared for CGT roll out. With the aim to bring CGT’s to as many patients as possible, this session will explore the latest trends and advancements in cell and gene therapy, and how they are shaping the future of life science industry. 

  • What do you see as the major head and tailwinds in CGT? 
  • CGT in the Nordics – is there an ecosystem? What could be done to strengthen it? 
  • What would you point to as the major success story over the past year in GCT? 
  • Areas with growth potential for future CGT pipelines 
  • Consideration of applying sciences across therapeutic areas 
Moderator: Josef Christensen, Chief Business Development Officer, StemMedical 
Johan Liwing, CEO, XNK therapeutics 
Kristian Tryggvason
, CEO, Alder Therapeutics 
Juha Yrjänheikki,
CEO, Aurealis Therapeutics 
Thomas Tan
, Principal, Sound Bioventures 

Josef Christensen, Chief Business Development Officer, StemMedical Johan Liwing, CEO, XNK therapeutics Kristian Tryggvason, CEO, Alder Therapeutics Juha Yrjänheikki, CEO, Aurealis Therapeutics Thomas Tan, Principal, Sound BioventuresJosef Christensen, Chief Business Development Officer, StemMedical


15:30 Afternoon Break


16:00 Building A Strong Ecosystem For SMEs: Resources In The Nordics To Help Biotechs Grow 

  • Building a strong ecosystem for life science innovation
  • How can the Nordics continue to foster a strong ecosystem for SMEs in the biotech industry?
  • Examples of alternative resources for biotechs
  • Openness for collaboration and dare to share 
Yorick Kamlag, Executive Director, BD, BioVentureHub AstraZeneca 
Anu Meerwaldt, Development Manager, SPARK Finland 
Anna Bergstrand
, Programme Manager, Vinnova 
Farzad Abdi-Dezfuli
, Partner, Sarsia Management 

_Johan Strömquist President NDA Group Yorick Kamlag, Executive Director, BD, BioVentureHub AstraZeneca Anu Meerwaldt, Development Manager, SPARK Finland Anna Bergstrand, Programme Manager, Vinnova Farzad Abdi-Dezfuli, Partner, Sarsia Seed (1)


16:50 Biopharma S&E And Dealmaking In 2023 And Beyond: What’s Next? 

New innovations are needed and new ideas fuel growth, but what new innovations and technologies does the world currently need?
This panel gathers top dealmakers at some of the world’s leading big pharma companies, discussing S&E, innovations, and adapting to a constantly shifting environment. 

  • Large pharma – what’s the new strategic perspective in terms of S&E?
  • How are some of the top deal makers at large pharma currently viewing the field in terms of innovation? Where are the gaps?
  • How can biotechs adapt to this ever-changing environment?
Moderator: Ahmed Mousa, CEO, Vicore Pharma  
Jennifer Laird, VP, Search & Evaluation, Eli Lilly 
Nathalie ter Wengel
, European Lead Worldwide Business Development, Pfizer 
Zaki Salanti
, Senior Director Head of S&E, Novo Nordisk
Bradley Hardiman,  Senior Director, Ventures and Scouting & Transactions – Business Development, Astellas Pharma  

Ahmed Mousa, CEO, Vicore Pharma Jennifer Laird, VP, Search & Evaluation, Eli Lilly Nathalie Ter Wengel 300xZaki Salanti, Head of S&E, Novo NordiskBradley Hardiman, Senior Director, Scouting & Transaction, Astellas Pharma


17:30 Drinks Reception 

 

Day 2 – Wednesday 11th October

 

09:00 Welcome Address


Adam Griffiths, Senior Conference Director, LSX


09:10 Keynote Panel: Paving The Way For Future Founders: Transitioning From Academic Leadership To Biotech Entrepreneurship 

Moving from academia to industry is a significant change for a scientist, but if you are doing it for the right reasons, have a clear path in mind and fully understand the road you are embarking on, it is a decision that can reap huge rewards. Becoming a biotech leader of tomorrow requires a specialized skillset to ensure efficient and stellar development from pre-clinical studies through to market approval.
This panel will discuss how academic founders can set themselves up for success by knowing the key milestones to prepare for, the importance of biotech company culture, and ultimately how to become a strong life science leader.

  • Surrounding yourself with key information – navigating the market, funding sources, regulatory requirements, and team management
  • Necessary resources to turn ideas into successful ventures
  • Building a strong team and creating an inspiring company culture
  • Calculated risks and pivoting when necessary
Moderator: Nina Haldipur, Director, Therapeutics Business Development, BioInnovation Institute 
Mette Kirstine Agger
, Senior Advisor, Esrum Biotech 
Claus Andersson, General Partner, Sunstone Ventures 
John Haurum
, Advisor and Nonexecutive Director, Multiple Biotechs 
Henrik Stage
, Co-founder & CEO, Fuse Vectors 

Nina Haldipur Senior Investment Manager VækstfondenMette Kirstine Agger, Strategic Advisor, Life Science CompaniesClaus Andersson, General Partner, Sunstone Ventures JOHN HAURUMHenrik Stage, CEO, Fuse Vectors


09:50 The Danish Enterprise Foundation Model: Investing In The Future For Long-term Success 

Some of Denmark’s largest pharma companies are all partly owned by independent foundations with dual philanthropic and commercial activities. This model ensures great stability to companies, allowing organizations to be set-up for long-term success and funds channelled into both academia and biotech start-ups. As a rapidly and ever-developing biotech hub, what are the direct and indirect benefits of this model, and what could other countries learn from Denmark? 

  • How is this model supporting and growing the biotech sector? 
  • What are the direct benefits and challenges? 
  • What could others learn from this model to continue to grow and internationalize the Nordic region? 
Moderator: Christian Elling, Managing Partner, Lundbeckfonden BioCapital  
Marianne Philip, Attorney, Kromann Reumert 
Trine Bartholdy, Chief Innovation Officer, BioInnovation Institute 
Jens Kann Rasmussen, Chair, Velux Foundations 
Mikkel Skovborg, SVP Innovation, Novo Nordisk Fonden 
Jakob Riis, CEO, Falck 
Mark Ørberg, Assistant Professor, CBS 

Christian Elling, Managing Partner Lundbeckfonden BioCapital  Marianne Philip, Attorney, Kromann Reumert Trine Bartholdy, Chief Innovation Officer, BioInnovation Institute Jens Kann Rasmussen, Chair, Velux Foundations  Mikkel Skovborg, SVP Innovation, Novo Nordisk Fonden Jakob Riis, CEO, Falck  Mark Ørberg, Assistant Professor, CBS


 10:30 Morning Break

11:00 Effective Talent Acquisition And Retention Strategies For Life Sciences In The Nordics   
  • What are the best practices for Nordic companies to increase recruitment of non-Nordic employees?
  • What strategies can companies employ to thrive in a competitive market and achieve growth?
  • How can organizations address talent-related issues and optimize their global talent and team structure to attract and retain top talent?
  • How can we continue to showcase the Nordic life sciences as a top environment for new career opportunities and development

Moderator: Nanna Soni, Client Partner, Coulter Partners
Jeroen Bakker
, Principal Seed Investment, Novo Holdings 
Annette Säfholm, CEO, Geada Biotech  
Christina Herder, Member of the Board, Elicera Therapeutics & Beactica AB

Nanna Soni,  Client Partner, Coulter PartnersJeroen Bakker, Principle, Novo Seeds, Nova HoldingsAnnette Säfholm, CEO, Gedea BiotechChristina Herder, Acting CEO, Idogen AB


11:50 Through The Lens: An International Investor’s Take On The Thriving Nordic Life Science Market  

The Nordic region has been experiencing rapid growth in its life science market in recent years, attracting the attention of international investors. As new innovations come to light and competition between companies increases, biotechs who know how to navigate the international investor community will set themselves up for future success. A panel of international biotech investors discuss the Nordic market, and how biotech companies can best position themselves for investment utilising intellectual property. 

  • How are international investors currently viewing the Nordic life sciences market? 
  • What are the top areas of innovation attracting investment, and how does the Nordic region compare to wider markets? 
  • What intellectual property aspects are investors looking for that can set up biotechs for future success? 
  • Where does the Nordic region excel in comparison to the rest of the EU and the US, and what could the Nordic region learn from international markets? 
  • What role does an intellectual property strategy play in the rapidly growing Nordic life science market? 

Moderator: Louise Jonshammar, Partner, AWA
Vanela Bushi
, Co-founder & Partner,  H Tree Capital
Ivan Burkov
, Junior Partner, INKEF 
Nico Straub
, Partner, Bioventure 
Giovanni Rizzo
, Partner, Indaco Venture Partners 
Louise Jonshammar, Partner, AWAVanela Bushi, Co-founder & Partner, H Tree PartnersIvan Burkov, Principal, INKEF Capital  Nico Straub, Partner, Bioventure Giovanni Rizzo, Venture Partner, Indaco Venture Partners


12:40 Lunch Break

14:00 How Artificial Intelligence Is Shaping The Future Of Drug Discovery, Design, And Development

The pharmaceutical industry is increasingly utilising artificial intelligence (AI) to bring novel treatments to market more rapidly and at a reduced cost. AI and machine learning (ML) have already transformed the way research and drug development are carried out, and these technologies are opening up many new possibilities for innovation in drug development. ML algorithms capable of providing insight and predictions can assist healthcare practitioners, delivering risk factors, diagnoses and treatments for patients earlier on in their care pathway and disease progression.
  • The opportunity for AI-enabled drug discovery and development
  • Can too much data be a bad thing?
  • Are we using all of our data and are we using it in the right way?
  • What are the challenges ahead for the use of AI in drug development?
Moderator: Marko Kuisma, Partner, Innovester 
Andreas Holm Mattsson, Founder, Chief AI & Culture Officer, Evaxion Biotech 
Alex Zhavoronkov, CEO, Insilico Medicine 
Marko Kuisma, Partner, Innovestor Andreas Holm Mattsson, Founder, Chief AI & Culture Officer, Evaxion Biotech Alex Zhavoronkov, CEO, Insilico Medicine (1)



14:50 Revolutionizing Oncology Drug Discovery: Novel Approaches And Technologies Shaping The Future Of Cancer Treatment 

In 2023, oncology, remains the focus of the majority of life sciences companies, comprising roughly 38% of all products currently with an active research programme, and has grown at 10.5% CAGR over the last five years. With an increased interest in platforms such as cancer vaccines, oncolytic viruses, and targeted protein degradation, what are the latest trends and developments in oncology, and how will this affect future partnering opportunities?
  • Oncology drug discovery in 2023 – what’s the current playing field?
  • Early detection – what’s needed to get us where we need to be?
  • Strengthening partnerships between patient advocates and scientists
  • Hot up and coming trends within oncology drug discovery – what’s on the horizon?
  • Oncology drug discovery in 2024 – how will next year’s field compare to this one?
Francois Martelet, CEO, Scandion Oncology 
Søren Bregenholt
, CEO, Alligator Bioscience
Lars Gredsted, Senior Principal, Lundbeckfonden BioCapital

Francois_Martelet-e1437036906773-150x150Søren Bregenholt, CEO, Alligator BioscienceLars Gredsted, Senior Principal, Lundbeckfonden BioCapital


15:30 Close of LSX Nordic Congress 2023

Company Showcases


 

Day 1 – Tuesday 10th October

10:45 Alder Therapeutics logo 150 300
11:00 PharmNovo-1
11:15 Oncoinvent 150 300
11:30 BioGrail
11:45 StemSight Oy
12:00 Empros Pharma 300 150
12:15 Tenboron 300 150
12:30 Kripthonite Therapeutics 300 150
Lunch  
13:45 Hemispherian-1
14:00 Amyl Therapeutics
14:15 Cbio logo
14:30 Gate2Brain 150 300

 

14:45 Adjutec Pharma 150 300

 

15:00 Zerion Pharma 150 300

 

15:15 Synartro Logo

 

 

Day 2 – Wednesday 11th October

10:45 LivaHealthcare 150 300

 

11:00 DoMore Diagnostics Logo

 

11:15 Cerebriu logo

 

11:30 Ventriject 150 300 (1)

 

11:45

 PILA PHARMA Logo

 

12:00 Pharma Holdings 150 300

 

12:15

 PU Sensor 150 300

 

12:30

 RSP Systems 150 300

 

12:45

 

 

 

LSX Biotech Public CEO Forum-1Day 1 - Tuesday 10th October - 11:00

 

The LSX Nordic Public CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between up 15-25 c-suite executives from publicly listed, life sciences companies from the Nordic region. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes that will drive their businesses and the sector forward. 

The forum is an invitation-only CEO forum where all participants are active discussants. It follows a Chatham House Rule policy and includes presentations, case studies and general discussion focused on brainstorming solutions to the current collective challenges of the group. 

The forum features interactive peer review discussions from CEOs and Partners who put forward informative presentations or specific case studies, either success stories or current challenges, and the group asks questions and discusses the challenges around the topic, as well as solutions and ideas.  

Some notes: 

  • Time will be managed carefully, with plenty of time for discussion
  • Each speaker is asked to communicate a clear message & solicit specific feedback
  • The moderator will be briefed to guide the discussion to touch on all participants' concerns 

Co-hosted by:

DNB Backbay logo 150 300 (1)Nasdaq Logo


11:00 Welcome Remarks - LSX 


11:05 Capital Markets Overview

Carsten Borring, Head of Listings & Capital Markets, Nasdaq Copenhagen 

Peter Legind-Hansen, Managing Director, Nasdaq Copenhagen 

Carsten Borring, Associate Vice President Listings EMEA and Head of Listings & Capital Markets, NASDAQPeter Legind-Hansen, Managing Director, Nasdaq Copenhagen


11:25 Crossing The Financing Oceans: Optimal Approaches To The US Private And Public Capital Markets 
 

Jonathan Gertler, Managing Partner and CEO, Back Bay Life Science Advisors

Jonathan Gertler, Managing Partner & CEO, Back Bay Life Science Advisors 300x


11:25 CEO-led case study

Hans Schambye, CEO, Galecto

Hans Schambye, President & CEO, Galecto


12:05 CEO-led case study

 


12:25 General Discussion 


Topics to include:

  • Managing through the public markets downturn 
  • Alternative strategies and deals while public capital is scarce 
  • Optimal strategies for accessing US capital and partners 

12:45 End of Forum

 

 

LSX Biotech Growth CEO Forum

Day 1– Tuesday 10th October - 15:45

The LSX Nordic Growth CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from privately-held life science companies from the Nordic region. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes that will drive their businesses and the sector forward. 

The forum is an invitation-only CEO forum where all participants are active discussants. It follows a Chatham House Rule policy and includes presentations, case studies and general discussion focused on brainstorming solutions to the current collective challenges of the group. 

The forum features interactive peer review discussions from CEOs and Partners who put forward informative presentations or specific case studies, either success stories or current challenges, and the group asks questions and discusses the challenges around the topic, as well as solutions and ideas.  

Some notes: 

  • Time will be managed carefully, with plenty of time for discussion
  • Each speaker is asked to communicate a clear message & solicit specific feedback
  • The moderator will be briefed to guide the discussion to touch on all participants concerns 

Co-hosted by:

Nasdaq LogoMintz Logo

 


 

15:45  Welcome Remarks - LSX 


15:50 Capital Markets Overview 

Carsten Borring, Head of Listings & Capital Markets, Nasdaq Copenhagen 

Peter Legind-Hansen, Managing Director, Nasdaq Copenhagen

Carsten Borring, Associate Vice President Listings EMEA and Head of Listings & Capital Markets, NASDAQPeter Legind-Hansen, Managing Director, Nasdaq Copenhagen


16:10 Accessing US Capital & Partners  

  • What’s currently being seen in private investment market and the public markets 
  • What is being seen in the IPO and reverse merger markets in the US 
  • What are investors focusing on in this environment 
  • Focussing on core strengths and strategies for mitigating current risks 

Bill Hicks, Co-chair, Securities & Capital Markets, Mintz

Bill Hicks, Co-Chair Securities and Capital Markets Practice Group, Mintz


16:30 Early engagement with big pharma: A case study 

  • The rationale behind early engagement 
  • Process pitfalls and key learnings 
  • Keeping the momentum 

Johan Liwing, CEO, XNK Therapeutics 

Johan Liwing, CEO, XNK therapeutics


16:50 CEO-led case study

 


17:10 General Discussion 
Topics to include:

  • How can private companies manage through the economic downturn? 
  • When will a new IPO window open, and how to be ready to capitalise? 
  • Building international success and securing international investment and partners 
  • Capitalising on the growth in the Nordic life sciences ecosystem 

17:30 End of Forum